Detlev Boison

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. pmc Neonatal hepatic steatosis by disruption of the adenosine kinase gene
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:6985-90. 2002
  2. ncbi Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Neuroscientist 11:25-36. 2005
  3. ncbi Seizure suppression by adenosine-releasing cells is independent of seizure frequency
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 43:788-96. 2002
  4. ncbi Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Brain 128:2383-95. 2005
  5. ncbi Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants
    Martin Güttinger
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Epilepsia 46:1162-9. 2005
  6. ncbi Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis
    Nicolette Gouder
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurosci 24:692-701. 2004
  7. pmc Manipulation of adenosine kinase affects sleep regulation in mice
    Svitlana Palchykova
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurosci 30:13157-65. 2010
  8. ncbi Adenosine A1 receptors are crucial in keeping an epileptic focus localized
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Exp Neurol 200:184-90. 2006
  9. ncbi Engineering embryonic stem cell derived glia for adenosine delivery
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Neurosci Lett 370:160-5. 2004
  10. doi Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition
    Hanns Mohler
    Institute of Pharmacology, University and ETH Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Biochem Pharmacol 81:1065-77. 2011

Collaborators

Detail Information

Publications34

  1. pmc Neonatal hepatic steatosis by disruption of the adenosine kinase gene
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:6985-90. 2002
    ..Thus, a deficiency in adenosine metabolism is identified as a powerful contributor to the development of neonatal hepatic steatosis, providing a model for the rapid development of postnatally lethal fatty liver...
  2. ncbi Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Neuroscientist 11:25-36. 2005
    ..Adenosine-releasing cells or devices implanted into or near a seizure focus offer new hopes for a side effect-free therapy for pharmacoresistant epilepsy...
  3. ncbi Seizure suppression by adenosine-releasing cells is independent of seizure frequency
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 43:788-96. 2002
    ..We tested whether the suppression of seizures by adenosine-releasing grafts was independent of seizure frequency...
  4. ncbi Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Brain 128:2383-95. 2005
    ..We therefore conclude that therapeutic strategies that augment the adenosine system after astrogliosis-induced upregulation of ADK constitute a neurochemical rationale for the prevention of seizures in epilepsy...
  5. ncbi Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants
    Martin Güttinger
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Epilepsia 46:1162-9. 2005
    ..The aim of the present study was to investigate the potential of differentiated Adk-/- ES cell progeny for seizure suppression by paracrine adenosine release...
  6. ncbi Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis
    Nicolette Gouder
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurosci 24:692-701. 2004
    ..We conclude that overexpression of adenosine kinase in discrete parts of the epileptic hippocampus may contribute to the development and progression of seizure activity...
  7. pmc Manipulation of adenosine kinase affects sleep regulation in mice
    Svitlana Palchykova
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurosci 30:13157-65. 2010
    ..Our data suggest that overexpression of the cytoplasmic isoform of ADK is sufficient to alter sleep physiology. ADK might orchestrate neurotransmitter pathways involved in the generation of EEG oscillations and regulation of sleep...
  8. ncbi Adenosine A1 receptors are crucial in keeping an epileptic focus localized
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Exp Neurol 200:184-90. 2006
    ..These results open up a new dimension of the A1 receptor's role in controlling excitotoxic cell death and further demonstrate its importance in preventing the progression of status epilepticus to lethal consequences...
  9. ncbi Engineering embryonic stem cell derived glia for adenosine delivery
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Neurosci Lett 370:160-5. 2004
    ..1 +/- 6.0 ng per 10(5) cells per hour, an amount considered to be sufficient for seizure suppression. Our findings indicate that Adk-/- ES cells constitute a potential source for therapeutic adenosine releasing grafts...
  10. doi Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition
    Hanns Mohler
    Institute of Pharmacology, University and ETH Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Biochem Pharmacol 81:1065-77. 2011
    ..Thus, interventions at GlyT1 are highly effective in modifying multiple brain functions, and dissection of their respective mechanisms is expected to further maximize their therapeutic potential for human mental diseases...
  11. ncbi Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts
    Martin Güttinger
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Exp Neurol 193:53-64. 2005
    ..Thus, the local release of adenosine by cellular implants provides a feasible option for a potential side-effect free approach for the long-term treatment of focal epilepsies...
  12. ncbi Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression
    Laetitia Gabernet
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstr 190, CH 8057 Zurich, Switzerland
    Neurosci Lett 373:79-84. 2005
    ..Thus, GlyT1 function is a controlling factor for an enhancement of the NMDA receptor response. These findings are of relevance for the development of GlyT1 inhibitory drugs...
  13. ncbi Amino acid composition of brain cysts: levels of excitatory amino acids in cyst fluid fail to predict seizures
    Heinz Gregor Wieser
    Department of Neurology, University Hospital, University of Zurich, Frauenklinikstrasse 26, CH 8091 Zurich, Switzerland
    Epilepsy Res 55:191-9. 2003
    ..In summary, there is no evidence for a close correlation between excitatory amino acids in brain cysts and the occurrence of seizures...
  14. ncbi Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy
    Nicolette Gouder
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 44:877-85. 2003
    ..In the present study, activation of the adenosine system was applied as a possible treatment for pharmacoresistant epilepsy...
  15. ncbi Adenosine-based cell therapy approaches for pharmacoresistant epilepsies
    Detlev Boison
    NCCR Neural Plasticity and Repair, University and ETH Zurich, Zurich, Switzerland
    Neurodegener Dis 4:28-33. 2007
    ..This review summarizes the rationale and recent approaches for adenosine-based cell therapies for pharmacoresistant epilepsies...
  16. ncbi Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy
    Alexander Huber
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Neurosci Lett 329:289-92. 2002
    ....
  17. doi Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology, Zurich, Institute of Pharmacology, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Pharmacol Biochem Behav 90:58-64. 2008
    ..Taken together, these results qualify distinct GABA-A receptor subtypes and GlyT1 as molecular targets for the development of a new pharmacology in the treatment of cognitive decline and psychotic symptoms...
  18. ncbi The use of real-time PCR with fluorogenic probes for the rapid selection of mutant neuroectodermal grafts
    Valérie Zumsteg
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057, Zurich, Switzerland
    J Neurosci Methods 120:85-94. 2002
    ..The method described here suggests the feasibility to graft adenosine releasing neuroectodermal cells as a potential therapeutic approach for the treatment of pharmacoresistant epilepsy...
  19. ncbi Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants
    Tianfu Li
    R S Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Brain 130:1276-88. 2007
    ..These findings may indicate a potential antiepileptogenic function of stem cell-mediated adenosine delivery...
  20. pmc Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control
    Gaoying Ren
    Robert S Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Exp Neurol 208:26-37. 2007
    ....
  21. pmc Adenosine as a neuromodulator in neurological diseases
    Detlev Boison
    Legacy Research, R S Dow Neurobiology Laboratories, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Curr Opin Pharmacol 8:2-7. 2008
    ..A new era of adenosine-based therapies has begun, with the prospect to cover a wide range of neurological diseases...
  22. ncbi entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse
    Julia Brill
    Institut fur Biochemie, Emil Fischer Zentrum, Friedrich Alexander Universitat Erlangen Nurnberg, D 91054 Erlangen, Germany
    J Biol Chem 279:7322-30. 2004
    ..entla is allelic to ducky and ducky2J, representing the third murine Cacna2d2 allele identified and so far the only one encoding an untruncated protein that is incorporated into membranes...
  23. ncbi Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 27:919-27. 2007
    ..We conclude that ES cell derived adenosine-releasing brain implants provide neuroprotection by synergism of endogenous precursor cell-mediated effects and paracrine adenosine release...
  24. ncbi Transgenic overexpression of adenosine kinase aggravates cell death in ischemia
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 27:1-5. 2007
    ..We conclude that pathologic overexpression of ADK as in epilepsy may also render the brain more susceptible to injury from ischemia. Consequently, ADK emerges as a rational therapeutic target to enhance neuroprotection...
  25. ncbi Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 28:17-23. 2008
    ..Thus, transient downregulation of hippocampal ADK after stroke might be a protective mechanism during maturation hippocampal cell loss...
  26. ncbi The support of adenosine release from adenosine kinase deficient ES cells by silk substrates
    Lorenz Uebersax
    Institute for Pharmaceutical Sciences, Drug Formulation and Delivery, ETH Zurich, CH 8093 Zurich, Switzerland
    Biomaterials 27:4599-607. 2006
    ..Taken together, these results suggest that silk matrices are particularly suitable biomaterials for ESC encapsulation and for the design of adenosine releasing bioincubators for the treatment of epilepsy...
  27. ncbi Adenosine kinase, epilepsy and stroke: mechanisms and therapies
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97202, USA
    Trends Pharmacol Sci 27:652-8. 2006
    ..A new era of cell-based delivery of adenosine has begun, which holds great promise for novel therapies for epilepsy and stroke...
  28. ncbi Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs
    Benjamin K Yee
    Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology Zurich, Schwerzenbach, Switzerland
    Eur J Neurosci 26:3237-52. 2007
    ..The present findings are of relevance to current pathophysiological hypotheses of schizophrenia and its pharmacotherapy...
  29. pmc Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice
    Tianfu Li
    Robert S Dow Neurobiology Laboratories, Legacy Clinical Research, Portland, Oregon 97232, USA
    J Clin Invest 118:571-82. 2008
    ..Our findings suggest that astrocyte-based ADK provides a critical link between astrogliosis and neuronal dysfunction in epilepsy...
  30. ncbi Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons
    Philipp Singer
    Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology Zurich, Switzerland
    Behav Neurosci 121:815-25. 2007
    ....
  31. doi Adenosine as a modulator of brain activity
    Detlev Boison
    R S Dow Neurobiology Laboratories, Portland, Oregon 97232, USA
    Drug News Perspect 20:607-11. 2007
    ..Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies...
  32. pmc Silk polymer-based adenosine release: therapeutic potential for epilepsy
    Andrew Wilz
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Biomaterials 29:3609-16. 2008
    ..Histological analysis of brain samples confirmed the correct location of implants and electrodes. We conclude that silk-based delivery of around 1000ng adenosine per day is a safe and efficient strategy to suppress seizures...
  33. ncbi Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile
    Benjamin K Yee
    Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology, 8603 Schwerzenbach, Switzerland
    J Neurosci 26:3169-81. 2006
    ....
  34. pmc The adenosine kinase hypothesis of epileptogenesis
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA
    Prog Neurobiol 84:249-62. 2008
    ..iv) Intrahippocampal implants of stem cells engineered to lack ADK prevent epileptogenesis. Thus, ADK emerges both as a diagnostic marker to predict, as well as a prime therapeutic target to prevent, epileptogenesis...